Medicament based on 2-amino-6-trifluoromethoxy-benzothiazole

• US 4,370,338 A
• Filed: 10/05/1981
• Issued: 01/25/1983
• Est. Priority Date: 10/17/1980
• Status: Expired due to Term

• Current Assignee: Pharmindustrie
• Original Assignee: Pharmindustrie
• Inventors: Mizoule, Jacques
• Primary Examiner(s): Meyers, Albert T.
• Assistant Examiner(s): ROLLINS, JOHN W
• Application Number:
  US06/308,695
• Time in Patent Office: 477 Days
• Field of Search: 424/270, 548/152, 548/164
• US Class Current: 514/367
• CPC Class Codes: A61K 31/425 Thiazoles
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: C07D 277/82 Nitrogen atoms

Abstract

Anticonvulsant, anxiolytic and hypnotic medicament containing, as active substance, 2-amino-6-trifluoromethoxy-benzothiazole or a salt of this compound with a pharmaceutically acceptable acid.

Claims

1. A medicament, particularly useful as an anticonvulsant, anxiolytic and hypnotic, which contains a pharmaceutically acceptable vehicle and, as active substance, 1 to 50 mg per unit dose of 2-amino-6-trifluoromethoxy-benzothiazole or a salt of this compound with a pharmaceutically acceptable acid.

2. A medicament according to claim 1 wherein the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, methanesulfonic and ethanedisulfonic acids.

3. A medicament according to claim 1 in the form of a compressed tablet containing 10 mg to 50 mg of active substance.

4. A medicament according to claim 1 in the form of a gelatin-coated pill containing 25 mg of active substance.

5. A medicament according to claim 1 in the form of a suppository containing 10 mg of active substance.

6. A process for treating a human suffering from convulsions or anxiety which comprises orally administering to said human 5 to 250 mg per day of 2-amino-6-trifluoromethoxy-benzothiazole or a salt thereof with a pharmaceutically acceptable acid.

7. A process according to claim 6 wherein the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, methanesulfonic and ethanedisulfonic acids.